Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?

Karer, Matthias; Stiasny, Karin; Zeitlinger, Markus; Jilma, Bernd

Karer, Matthias; Stiasny, Karin; Zeitlinger, Markus; Jilma, Bernd.

Karer M; Department of Clinical Pharmacology.
Stiasny K; Center for Virology, Medical University of Vienna, Vienna, Austria.
Zeitlinger M; Department of Clinical Pharmacology.
Jilma B; Department of Clinical Pharmacology.

Blood Coagul Fibrinolysis ; 32(6): 423-424, 2021 09 01.

Article in English | MEDLINE | ID: covidwho-1358515

Subject(s)

Anticoagulants/adverse effects; COVID-19 Vaccines/administration & dosage; COVID-19/prevention & control; Hemorrhage/prevention & control; Hemorrhagic Disorders/complications; SARS-CoV-2/immunology; Adult; Antibodies, Neutralizing/biosynthesis; Antibodies, Viral/biosynthesis; Autoexperimentation; BNT162 Vaccine; COVID-19 Vaccines/adverse effects; Chills/etiology; Contraindications, Procedure; Fatigue/etiology; Hemorrhage/chemically induced; Hemorrhage/etiology; Humans; Injections, Intramuscular/adverse effects; Injections, Subcutaneous; Male; Middle Aged; Punctures/adverse effects; Rivaroxaban/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Hemorrhage / Hemorrhagic Disorders / Anticoagulants Topics: Long Covid / Vaccines Limits: Adult / Humans / Male / Middle aged Language: English Journal: Blood Coagul Fibrinolysis Journal subject: Vascular Diseases / Hematology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google